Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;148(5):1208-1218.
doi: 10.1002/ijc.33366. Epub 2020 Nov 21.

Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting

Daniel R S Middleton  1 , Blandina T Mmbaga  2   3   4 , Maria O'Donovan  5 , Behnoush Abedi-Ardekani  6 , Irene Debiram-Beecham  7 , Gissela Nyakunga-Maro  2   3   4 , Venance Maro  3   4 , Martin Bromwich  5 , Amini Daudi  2   3 , Timothy Ngowi  2 , Rehema Minde  3 , Jackson Claver  3 , Alex Mremi  3   4 , Amos Mwasamwaja  2   3   4 , Joachim Schüz  1 , Rebecca C Fitzgerald  7 , Valerie McCormack  1
Affiliations

Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting

Daniel R S Middleton et al. Int J Cancer. .

Abstract

Esophageal sponge cytology is an endoscopy alternative well accepted by patients with extensive data for accuracy in the context of adenocarcinoma. Few studies have assessed its feasibility in asymptomatic community members, and fewer still in East Africa, where esophageal squamous cell carcinoma (ESCC) rates are high. We aimed to assess the feasibility of a capsule-based diagnosis of esophageal squamous dysplasia (ESD), an ESCC precursor, which may benefit epidemiological and early detection research. We collected Cytosponge collections in 102 asymptomatic adults from Kilimanjaro, Tanzania. Uptake, acceptability and safety were assessed. Participants scored acceptability immediately following the procedure and 7 days later on a scale of 0 (least) to 10 (most acceptable). Slides from paraffin-embedded cell clots were read by two pathologists for ESD and other pathologies. All participants (52 men, 50 women, aged 30-77) swallowed the device at first attempt, 100 (98%) of which gave slides of adequate cellularity. Acceptability scores were 10 (53%), 9 (24%), 8 (21%), 7 (2%) and 6 (1%), with no differences by age, sex or time of asking. Cytological findings were esophageal inflammation (4%), atypical squamous cells of uncertain significance (1%), low-grade dysplasia (1%), gastritis (22%) and suspected intestinal metaplasia (6%). Setting-specific logistical and ethical considerations of study implementation are discussed. We demonstrate the safety, acceptability and feasibility of Cytosponge sampling in this setting, paving the way for innovative etiology and early-detection research. Targeted sampling strategies and biomarker development will underpin the success of such initiatives. The study protocol is registered on ClinicalTrials.gov (NCT04090554).

Keywords: Africa; Cytosponge; esophageal cancer; squamous dysplasia.

PubMed Disclaimer

Conflict of interest statement

The Cytosponge device was designed by RCF and the MRC licensed the technology to Covidien GI Solutions, now part of Medtronic. Medtronic have had no influence on the design, conduct or analysis of this study. RCF and MOD are named inventors on patents pertaining to the Cytosponge and related assays. RCF and MoD are shareholders and consultants for Cyted Ltd. All other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Study recruitment flow chart
FIGURE 2
FIGURE 2
Immediate post‐Cytosponge procedure acceptability scores for all participants (n = 102)
FIGURE 3
FIGURE 3
Situation‐specific considerations of the Cytosponge administration in a new low‐resource setting. Considerations 1 to 3 are presented top to bottom along the cascade of planning, recruitment and follow‐up care, followed by overarching ethical considerations
See this image and copyright information in PMC

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424. - PubMed
    1. Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69:1564‐1571. - PubMed
    1. McCormack V, Menya D, Munishi M, et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting‐specific exposures to known and putative risk factors. Int J Cancer. 2017;140:259‐271. - PMC - PubMed
    1. McGlashan ND. Oesophageal cancer and alcoholic spirits in Central Africa. Gut. 1969;10:643‐650. - PMC - PubMed
    1. Wang G, Abnet C, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187‐192. - PMC - PubMed

Publication types

Associated data